You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

STRIANT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Striant, and when can generic versions of Striant launch?

Striant is a drug marketed by Auxilium Pharms Llc and is included in one NDA.

The generic ingredient in STRIANT is testosterone. There are sixty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the testosterone profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Striant

A generic version of STRIANT was approved as testosterone by ACTAVIS LABS UT INC on January 27th, 2006.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for STRIANT?
  • What are the global sales for STRIANT?
  • What is Average Wholesale Price for STRIANT?
Summary for STRIANT
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 73
Patent Applications: 4,285
Drug Prices: Drug price information for STRIANT
What excipients (inactive ingredients) are in STRIANT?STRIANT excipients list
DailyMed Link:STRIANT at DailyMed
Drug patent expirations by year for STRIANT
Drug Prices for STRIANT

See drug prices for STRIANT

US Patents and Regulatory Information for STRIANT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Auxilium Pharms Llc STRIANT testosterone TABLET, EXTENDED RELEASE;BUCCAL 021543-001 Jun 19, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for STRIANT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Auxilium Pharms Llc STRIANT testosterone TABLET, EXTENDED RELEASE;BUCCAL 021543-001 Jun 19, 2003 ⤷  Sign Up ⤷  Sign Up
Auxilium Pharms Llc STRIANT testosterone TABLET, EXTENDED RELEASE;BUCCAL 021543-001 Jun 19, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for STRIANT

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Warner Chilcott UK Ltd. Intrinsa testosterone EMEA/H/C/000634
Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
Warner ChilcottĀ  Deutschland GmbH Livensa testosterone EMEA/H/C/000630
Livensa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.
Withdrawn no no no 2006-07-28
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for STRIANT

See the table below for patents covering STRIANT around the world.

Country Patent Number Title Estimated Expiration
Norway 331255 ⤷  Sign Up
Peru 05192001 ⤷  Sign Up
Malaysia 125919 BIOADHESIVE PROGRESSIVE HYDRATION TABLETS AND METHODS OF MAKING AND USING THE SAME ⤷  Sign Up
South Africa 200104935 Extended release buccal tablet. ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.